The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences Inc. has entered into a co-marketing agreement with NanoMosaic, aiming to drive forward the development of next generation gene therapies.
The partnership focuses on unlocking the full potential of adeno-associated virus (AAV) technology, leveraging innovative capsid design approaches such as Solid Biosciences Inc.'s proprietary POLARIS-101 platform. Both companies intend to combine their expertise to support rapid advancements in precision genetic medicines.
View post on X Loading...
Solid Biosciences recently presented clinical insights into its SGT-003 gene therapy candidate for Duchenne muscular dystrophy at a leading scientific congress, according to a prior company update. The company is also slated to participate in the upcoming Jefferies Global Healthcare Conference, where CEO Bo Cumbo will lead a fireside chat on June 3, as noted in a recent announcement. These events contribute to Solid Biosciences' continued engagement with the gene therapy sector.